CoChat

CD137/OX40 Bispecific Antibody Induces Potent Antitumor Activity that Is Dependent on Target Coengagement

Published version of a preprint

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Abstract

Abstract Following the success of immune checkpoint blockade therapy against cancer, agonistic antibodies targeting T-cell costimulatory pathways are in clinical trials. The TNF superfamily of receptors (TNFRSF) members CD137 and OX40 are costimulatory receptors that stimulate T-cell proliferation and activation upon interaction with their cognate ligands. Activating CD137 and OX40 with agonistic mAbs stimulates the immune system due to their broad expression on CD4+ and CD8+ T cells and natural killer cells and has antitumor effects in preclinical models. Most TNFRSF agonist antibodies require crosslinking via Fcγ receptors (FcγR), which can limit their clinical activity. FS120 mAb2, a dual agonist bispecific antibody targeting CD137 and OX40, activated both CD4+ and CD8+ T cells in an FcγR-independent mechanism, dependent on concurrent binding. A mouse surrogate version of the bispecific antibody displayed antitumor activity in syngeneic tumor models, independent of T regulatory cell depletion and of FcγR interaction, but associated with peripheral T-cell activation and proliferation. When compared with a crosslink-independent CD137 agonist mAb, the FS120 surrogate induced lower liver T-cell infiltration. These data support initiation of clinical development of FS120, a first-in-class dual agonist bispecific antibody for the treatment of human cancer.

Overview

Integrity signals

Registry

Crossref · 10.1158/2326-6066.cir-19-0798

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 50 references

Research works printed but not linked: 1

  1. Segal, 2018, Phase I study of single-agent utomilumab (PF-05082566), a 4-1BB/CD137 agonist, in patients with advanced cancer, Clin Cancer Res, 24, 1816, 10.1158/1078-0432.CCR-17-1922 · DOI · Paper page

Cited by

See all 58

Metadata

Authors
Gaspar, M., Pravin, J., Rodrigues, L., Uhlenbroich, S., Everett, K. L., Wollerton, F., Morrow, M., Tuna, M., & Brewis, N.
Affiliations
F-star (United Kingdom) (GB)
Venue
Cancer Immunology Research
Published
2020-06-01
Volume
8
Issue
6
Pages
781-793
ISSN
  • 2326-6066 (ISSN-L)
  • 2326-6074
OpenAlex
W3015859054
Cited by
58
References
49
Citations by year
2026: 7 · 2025: 5 · 2024: 4 · 2023: 12 · 2022: 16 · 2021: 13 · 2020: 1
FWCI
3.81
Type
journal article
Language
en
Open access
closed
Locations
  • Cancer Immunology Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
Melanie Medcalf and Edouard Souteyrand (CD137, FS120)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
4-1BB, OX40, bispecific antibodies, agonistic antibodies, T cell costimulation, anticancer activity, T cell activation, cancer immunotherapy
MeSH terms
Animals, Colonic Neoplasms, Female, Humans, Immunotherapy, Killer Cells, Natural, Lymphocyte Activation, Mice, Inbred BALB C, Tumor Cells, Cultured, Apoptosis, Antibodies, Bispecific, Xenograft Model Antitumor Assays, Cell Proliferation, T-Lymphocytes, Regulatory, Mice, Tumor Necrosis Factor Receptor Superfamily, Member 9, Receptors, OX40

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CD137/OX40 Bispecific Antibody Induces Potent Antitumor Activity that Is Dependent on Target Coengagement. https://app.cochat.ai/papers/10.1158/2326-6066.cir-19-0798
The paper
Gaspar, M., Pravin, J., Rodrigues, L., Uhlenbroich, S., Everett, K. L., Wollerton, F., Morrow, M., Tuna, M., & Brewis, N. (2020). CD137/OX40 Bispecific Antibody Induces Potent Antitumor Activity that Is Dependent on Target Coengagement. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-19-0798

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.